{"id":"e36e6d86-498c-5a81-b7a2-ed1fdf28492d","stable_key":"488ea171-36b8-5ef6-b5d3-98563980fdbf:hbot-radiation-proctitis-improvement","predicate":"reduces","statement":"Mean SOMA-LENT score improvement was nearly twice as large in the treated group (5.00 versus 2.61), with more responders per clinical assessment (88.9% versus 62.5%) and an absolute risk reduction of 32%, and the differences were abolished after crossover.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"4f74b340-88e0-5469-bd78-e894a66ea16f","mechanism_event_label":"Most treated people improved, and the sham group improved too once they crossed over.","subject":{"id":"581fa746-cb84-571b-87a0-4d461263f660","slug":"hyperbaric-oxygen","display_name":"Hyperbaric oxygen therapy","entity_type_key":"drug"},"object":{"id":"edf44fa2-6b85-590d-916f-89a6b3fd512d","slug":"radiation-proctitis-severity","display_name":"Refractory radiation proctitis severity by SOMA-LENT score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4f74b340-88e0-5469-bd78-e894a66ea16f","stable_key":"488ea171-36b8-5ef6-b5d3-98563980fdbf:hbot-radiation-proctitis-improvement-event","event_type":"observed_intervention","label":"Most treated people improved, and the sham group improved too once they crossed over.","description":"Mean SOMA-LENT score improvement was nearly twice as large in the treated group (5.00 versus 2.61), with more responders per clinical assessment (88.9% versus 62.5%) and an absolute risk reduction of 32%, and the differences were abolished after crossover.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"581fa746-cb84-571b-87a0-4d461263f660","slug":"hyperbaric-oxygen","display_name":"Hyperbaric oxygen therapy","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"edf44fa2-6b85-590d-916f-89a6b3fd512d","slug":"radiation-proctitis-severity","display_name":"Refractory radiation proctitis severity by SOMA-LENT score","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/hbot-research/18342453.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e54a071083cc14d5dcb6461692588b064f94d560a91045313836b0dca18cfe85\", \"start_char\": 0, \"end_char\": 1963, \"text_sha256\": \"e54a071083cc14d5dcb6461692588b064f94d560a91045313836b0dca18cfe85\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomised controlled double-blind crossover trial of 150 patients with refractory radiation proctitis","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"2.0 atmospheres absolute versus air at 1.1 atmospheres absolute, with crossover","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A double-blind crossover trial with a sham arm and five-year follow-up. The crossover abolished the between-group difference, which is consistent with a real treatment effect.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Hyperbaric oxygen research collection; topical membership is not evidence of a direct clinical effect, and a therapeutic exposure is not a dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"hyperbaric-oxygen","display_name":"Hyperbaric oxygen therapy","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Most treated people improved, and the sham group improved too once they crossed over.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[hbot-p18342453] Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. (2008). https://pubmed.ncbi.nlm.nih.gov/18342453/ DOI: 10.1016/j.ijrobp.2007.12.048","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Rectal mucosa","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f8ca802f-f022-54d3-b550-2536934abae8","evidence_kind":"source_excerpt","locator":"Lines 1102-1113","start_line":1102,"end_line":1113,"excerpt":"### hbot-radiation-proctitis-improvement\nMean SOMA-LENT score improvement was nearly twice as large in the treated group (5.00 versus 2.61), with more responders per clinical assessment (88.9% versus 62.5%) and an absolute risk reduction of 32%, and the differences were abolished after crossover.\nCondition category: normal\nnutrient_topic: Hyperbaric oxygen research collection; topical membership is not evidence of a direct clinical effect, and a therapeutic exposure is not a dietary intake.\nplain_language: Most treated people improved, and the sham group improved too once they crossed over.\norganism: Human\ntissue_or_cell_type: Rectal mucosa\nexperimental_model: Randomised controlled double-blind crossover trial of 150 patients with refractory radiation proctitis\nlimitations: A double-blind crossover trial with a sham arm and five-year follow-up. The crossover abolished the between-group difference, which is consistent with a real treatment effect.\nexposure: 2.0 atmospheres absolute versus air at 1.1 atmospheres absolute, with crossover\nevidence_span: {\"source_cache\": \"artifacts/hbot-research/18342453.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e54a071083cc14d5dcb6461692588b064f94d560a91045313836b0dca18cfe85\", \"start_char\": 0, \"end_char\": 1963, \"text_sha256\": \"e54a071083cc14d5dcb6461692588b064f94d560a91045313836b0dca18cfe85\"}\n[hbot-p18342453] Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. (2008). https://pubmed.ncbi.nlm.nih.gov/18342453/ DOI: 10.1016/j.ijrobp.2007.12.048","model_system":"Randomised controlled double-blind crossover trial of 150 patients with refractory radiation proctitis","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [hbot-p18342453] Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. (2008). https://pubmed.ncbi.nlm.nih.gov/18342453/ DOI: 10.1016/j.ijrobp.2007.12.048","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dbf39b48-c95e-5291-b404-349ffbc4488f","stable_key":"import-488ea171-36b8-5ef6-b5d3-98563980fdbf","title":"Hyperbaric oxygen: the exposure, its reactive species, the signals they carry, and the nutrient-dependent enzymes that handle them (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"fb2443321804010d82c6b96ab61cc51b4b6628ddbb15751cb0e90b491606e79c","revision_id":"bb699ea5-b492-5728-b22c-48f0842a8ac9","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}